EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Comprehensive genomic landscape of ERBB2 in Chinese GI tumors: mutation-centered landscapes and precision treatment opportunities

Yinan Shi, Xiaoxuan Wang, Xiaotong Xi, Mengxiao Wang, Jinfang Guo, Xing Zhang, Dongsheng Chen, Wenhui Yang iD

Therapeutic Advances in Medical Oncology · 2026-05 · 18

DOI: 10.1177/17588359261445706 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 04.05.2026. Verfasst von Yinan Shi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shan…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Jiangsu Funding Program for Excellent Postdoctoral Talent, Beijing Science and Technology Innovation Medical Development Foundation Youth Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

ERBB2 aberrations are established oncogenic drivers with validated therapeutic relevance in breast cancer and emerging indications across solid tumors. In gastrointestinal malignancies, the prevalence, molecular contexts, and therapeutic implications of ERBB2 alterations remain incompletely defined, particularly for mutation-driven (non-amplified) disease.

Objectives

This study aimed to delineate the genomic landscape of ERBB2 alterations across colorectal cancer (CRC) and gastric cancer (GC), with emphasis on mutation versus amplification subtypes and their associated molecular contexts.

Design

This was a retrospective observational genomic cohort study based on next-generation sequencing (NGS) data from patients with gastrointestinal malignancies.

Methods

Tumors harboring ERBB2 alterations were identified through targeted NGS. Variants were annotated using InterVar and classified according to oncogenic significance. Alterations were mapped to HER2 functional domains and integrated with co-mutation patterns, copy number profiles, tumor mutational burden (TMB), and microsatellite instability (MSI) status to characterize subtype-specific genomic features.

Results

Across CRC and GC, ERBB2 mutations predominantly clustered within the HER2 kinase domain, with recurrent hotspots (R678Q, S310F/Y, L755S, V842I) largely classified as oncogenic or likely oncogenic. In CRC, ERBB2-mutant tumors frequently co-harbored alterations in APC, TP53, PIK3CA, ARID1A, and SMAD4, whereas ERBB2-amplified tumors showed co-gains in RARA, TOP2A, and SMARCE1. In GC, mutation-positive cases were enriched for APC, TP53, ARID1A, MUC16, and LRP1B alterations, while amplification was associated with EGFR and cell cycle regulators. Oncogenic ERBB2 mutation subgroups exhibited higher TMB and MSI-H enrichment than amplification-positive counterparts, with no material differences in overall copy-number burden between subtypes. These patterns indicate that non-amplified ERBB2-mutant tumors form a genomically distinct subset with potential immunogenic features.

Conclusion

ERBB2 alterations in CRC and GC converge on recurrent kinase domain hotspots but arise within tumor type-specific genomic milieus that likely influence therapeutic response. Compared with amplification, oncogenic ERBB2 mutations are preferentially associated with higher TMB/MSI-H and characteristic co-mutation signatures, supporting the clinical evaluation of mutation-selective HER2 inhibitors and rational combinations with immune checkpoint blockade. Our findings expand the molecular epidemiology of ERBB2 in Chinese GI cohorts, suggesting potential implications for resistance to standard chemotherapy or anti-EGFR strategies in select settings.

Schlagwörter

Stichwörter der Autor:innen

ERBB2colorectal cancergastric cancergenomicsoncogenic

Autor:innen und Institutionen

  • Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China.
  • State Key Laboratory of Neurology and Oncology Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing, China.
  • Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital affiliated to Shanxi Medical University, No. 3 of Zhigongxincun Road, Taiyuan, 030013, C…

ORCID-Profile: Wenhui Yang

Förderung

  • Jiangsu Funding Program for Excellent Postdoctoral Talent
  • Beijing Science and Technology Innovation Medical Development Foundation Youth Project

Zitieren

APA

Shi, Y., Wang, X., Xi, X., Wang, M., Guo, J., Zhang, X., Chen, D., & Yang, W. (2026). Comprehensive genomic landscape of ERBB2 in Chinese GI tumors: mutation-centered landscapes and precision treatment opportunities. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261445706

Vancouver

Shi Y, Wang X, Xi X, Wang M, Guo J, Zhang X, et al. Comprehensive genomic landscape of ERBB2 in Chinese GI tumors: mutation-centered landscapes and precision treatment opportunities. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261445706

BibTeX
@article{Shi2026,
  author = {Shi, Yinan and Wang, Xiaoxuan and Xi, Xiaotong and Wang, Mengxiao and Guo, Jinfang and Zhang, Xing and Chen, Dongsheng and Yang, Wenhui},
  title = {Comprehensive genomic landscape of ERBB2 in Chinese GI tumors: mutation-centered landscapes and precision treatment opportunities},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2026},
  volume = {18},
  doi = {10.1177/17588359261445706}
}
Kostenlos starten →